Objective: To evaluate whether T cell activation as refl ected by levels of sIL-2R, sCD30, IL-10 and B cell activator of the TNF family (BAFF) at diagnosis and during initial follow-up is predictive for persistent or renewed ANCA-positivity and clinical relapse in PR3-ANCAassociated vasculitis.
INTRODUCTION
Antineutrophil cytoplasmic antibodies against myeloperoxidase (MPO-ANCA) and proteinase 3 (PR3-ANCA) are associated with primary vasculitides aff ecting small to medium sized vessels [1, 2] . With current immunosuppressive induction therapy most patients with these diseases can be brought into stable remission. Patients positive for PR3-ANCA, however, are particularly prone for relapse of disease during long-term follow-up when immunosuppressive therapy is tapered and fi nally stopped [3] . Recently, we showed that persistence of a positive ANCA-titer in these patients aft er induction of remission by cyclophosphamide, at the time treatment is switched to azathioprine, is associated with an increased risk for relapse [4] .
Additionally we found positive c-ANCA and PR3-ANCA titres at 3, 12, 18 and 24 months aft er diagnosis were also associated with relapse [5] . We concluded from these data that ANCA positivity refl ects smouldering immune-activation, and is, therefore, associated with an increased risk for disease relapse when immunosuppressive therapy is tapered and stopped. Serological markers of immune activation are, indeed, present in active ANCAassociated vasculitis. Notably, serum levels of soluble IL-2 receptor (sIL-2R) and soluble CD30 (sCD30) are elevated during active disease refl ecting T cell activation [6] [7] [8] [9] . Th ey have been proposed as markers of disease activity. Moreover, not only in active disease but also during remission activated T cells can be present [10] . Recently, Ohlsson et al reported that the presence of low plasma levels of the immunosuppressive Th 2 cytokine IL-10 during remission is associated with an increased risk of subsequent relapse in ANCA-associated vasculitis [11] . In addition to activated T cells, patients with active ANCA-associated vasculitis have been shown to have increased numbers of activated B cells. In other autoimmune diseases elevated plasma levels of the polyclonal B cell stimulator BAFF (B cell activating factor of the TNF family) have been related to B cell activation [12] [13] [14] . BAFF stimulates B cells promoting their survival and BAFF itself might be produced by activated T cells. As BAFF is produced by activated T cells it might link activated T cells to B cell activation. We hypothesize that patients with PR3-ANCA-associated vasculitis who remain positive for ANCA aft er induction of remission, might have ongoing smouldering immuneactivation with an associated increased risk for relapse. In this study, we measured serial levels of the immune-markers sIL2R, sCD30, IL-10 and BAFF in patients with PR3-ANCAassociated vasculitis up to 24 months aft er diagnosis. We assessed their association with ANCA-status, disease activity, and relapse rate during long-term follow-up. We observed that patients positive for ANCA during remission had persisting increased T cell activation aft er tapering of immunosuppressives.
PATIENTS AND METHODS

Patients and ANCA assessment
Eighty-seven patients diagnosed with PR3-ANCA-associated vasculitis at our center between January 1991 and March 2002 and being followed for at least 2 years, were included in this retrospective study. Data of the patients are given in table 1. Patients were followed until March 2004. In all patients, the presence of PR3-ANCA was confi rmed by antigen specifi c enzyme-linked immunosorbent assay (ELISA) [1] . Induction treatment consisted of oral cyclophosphamide (2 mg/kg) and prednisolone (1 mg/kg; maximum dose of 60 mg/ day). Doses of cyclophosphamide were adjusted to maintain the white blood cell count above 4 x 10 9 /L. Aft er 4 to 6 weeks, the daily prednisolone dose was tapered by 10 mg every 2 weeks until the dose reached 30 mg, and thereaft er by 5 mg every 2 to 4 weeks. Once remission was achieved the daily dose of oral cyclophosphamide was tapered by 25 mg every 3 months during the period 1991-1996. From 1997 on, patients were switched to azathioprine (1.5-2 mg/kg body weight daily) aft er three months of stable remission with tapering by 25 mg every 3 months. At diagnosis, during follow-up and at relapse, disease activity was scored using the Birmingham Vasculitis Activity Score (BVAS) [15] . At diagnosis and at 3, 6, 12, 18, 24 months aft er diagnosis, and at relapse, serum ANCA titers were determined by indirect immunofl uorescence (IIF) as described previously [16] , and EDTA plasma was collected from each patient. Sera were considered positive for ANCA when a cytoplasmic staining pattern (C-ANCA) was present at a dilution of at least 1:40. Plasma samples were spun at 3000 rpm for 10 minutes, and supernatants were stored at -80°C until use. In plasma samples PR3-ANCA levels were determined by direct PR3-ANCA ELISA as described previously [17] .
Values were expressed as arbitrary units/ml; values of ≥10 units/ml were considered positive.
Th irty-one sex and age matched healthy laboratory workers (13 females, 18 males; median age 51; range: 44-67) volunteered and provided EDTA plasma specimens for comparison.
Defi nitions
Remission was defi ned as the absence of clinical signs and symptoms of active vasculitis (Birmingham Vasculitis Activity Score (BVAS)=0) in combination with a normal C-reactive protein (<10 mg/l). A relapse was defi ned as clinical signs of vasculitic activity in combination with biopsy proven vasculitic disease activity, or the occurrence of nodular pulmonary lesions aft er exclusion of infectious or malignant diseases. Renal vasculitic disease was defi ned as biopsy proven necrotizing glomerulonephritis or a combination of microscopic glomerular erythrocyturia, erythrocyte cell casts, proteinuria, and a decrease in creatinine clearance [18] .
Detection of soluble IL-2R, soluble CD30, IL-10, and BAFF
Soluble IL-2R (R&D systems; Oxon, UK), soluble CD30 (Bender MedSystems, Vienna, Austria) and IL-10 (Mabtech, Strand, Sweden) were detected by commercial sandwich enzyme-linked immunosorbent assays (ELISAs) according to the manufacturer's instructions.
Lowest levels of detection of the ELISAs were 32 pg/ml for sIL-2R, 0.5 U/ml for sCD30, and 0.5 pg/ml for IL-10. Plasma levels of BAFF were measured by a sandwich ELISA, developed in our laboratory, using a monoclonal antibody as capturing and a biotinylated polyclonal antibody as detecting antibody. In brief, 96-wells plates (Nunc, Maxisorb) were coated overnight at 4°C with 4 mg/ml mouse anti-human BAFF (clone 36006.211; R&D systems).
Aft er washing, plates were blocked with 2% bovine serum albumin (BSA), 0.05% Tween 20 in PBS for 60 minutes. Human plasma samples and recombinant BAFF were diluted in High Performance ELISA (HPE) buff er (Sanquin, Amsterdam, Th e Netherlands), added to the plate and incubated at room temperature for one hour. Aft er washing, bound BAFF was detected by a one hour incubation with biotinylated goat anti-human BAFF (PeproTech, NJ, USA). Aft er washing, samples were incubated with 0.125 mg/ml peroxidase conjugated streptavidin (Sanquin, Amsterdam, Th e Netherlands) for 30 minutes, and the colour reaction was performed with tetramethylbenzidin (TMB) (Roth, Karlsruhe, Germany).
Th e colorimetric reaction was stopped by the addition of 100 ml/well 0.5 M 2 N H 2 SO 4 .
Adsorption at 450/575 nm was measured with a microplate reader. Sensitivity of this ELISA to detect BAFF was 0.15 ng/ml. Plasma concentrations were determined by interpolation from a standard curve. 
Statistical analysis
RESULTS
Clinical characteristics
Fift y-two out of the 87 included patients (60%) experienced one or more relapses of disease, 26 patients (63%) in the group switched to azathioprine maintenance (n=41) and 26 patients (57%) in the group on cyclophosphamide (n=46 Aft er starting immunosuppressive therapy many patients became negative for ANCA:
at 6 months, 49% was negative for ANCA by ELISA and 69% negative for ANCA by IIF 
Soluble IL-2R
W e measured levels of the T cell activation marker sIL-2R during follow-up in PR3-ANCAassociated vasculitis. Plasma sIL-2R levels in patients with PR3-ANCA-associated vasculitis at diagnosis and during follow-up were signifi cantly higher than in healthy controls (p<0.01), except at 6 months aft er diagnosis (Figure 2a) . At diagnosis and at relapse, plasma sIL-2R levels correlated signifi cantly with BVAS (r=0.46, p < 0.001; r=0.40, p<0.01, respectively) (table 3) . Plasma sIL-2R levels at diagnosis were signifi cantly higher than at all time points during follow-up (p<0.05), apart from 24 months aft er diagnosis when levels did not signifi cantly diff er from sIL-2R levels at diagnosis (p=0.31) (Figure 2a) . Levels of sIL-2R fell aft er starting immunosuppressive therapy, but, subsequently, rose again. Accordingly, at 12, 18, and 24 months aft er diagnosis sIL-2R levels were signifi cantly higher than at 6 months aft er diagnosis (p=0.03; p=0.006; p=0.007, respectively).
Soluble IL-2R levels as measured at several time points during the fi rst 24 months of follow-up did not diff er between patients with a relapse within 5 years aft er diagnosis and those who did not relapse.
We analysed whether sIL-2R levels diff ered between patients positive for ANCA and patients negative for ANCA during follow-up. Only at 18 months aft er diagnosis, sIL-2R levels were signifi cantly higher in patients positive for PR3-ANCA by ELISA as compared to PR3-ANCA negative patients (p=0.022) (Figure 3a) . At all other time-points during followup, that is at 3, 6, 12, and 24 months aft er diagnosis, patients positive for ANCA did not have signifi cantly higher levels of sIL-2R as compared to patients negative for ANCA Plasma levels of sIL-2R correlated signifi cantly (p<0.01) with levels of sCD30 but not with CRP levels at diagnosis and at all time points during follow up.
Soluble CD30
Like sIL-2R, sCD30 is a marker of T cell activation. We evaluated sCD30 levels during follow-up in patients with PR3-ANCA-associated vasculitis. Plasma levels of sCD30 were signifi cantly higher in patients with PR3-ANCA associated vasculitis, both at diagnosis and during follow-up, than in controls (p<0.001) (Figure 2b ). Soluble CD30 could be detected in only 3 out of 31 control samples. Patients with PR3-ANCA associated vasculitis had higher sCD30 levels at diagnosis than at all time points during follow-up (p<0.05), apart from 24 months aft er diagnosis when this diff erence was not statistically signifi cant (p=0.054). At diagnosis, sCD30 levels correlated signifi cantly with BVAS (r=0.40, p = 0.003) (table 3) . In contrast, sCD30 levels were not signifi cantly higher at relapse than during follow-up, and did not correlate with BVAS (r=0.09, p= 0.56). sCD30 levels during follow-up did not diff er sIL-2R, sCD30, IL-10, BAFF in PR3-AAV | 57 between patients with a relapse and those who did not relapse. sCD30 levels at diagnosis were, however, signifi cantly higher in patients who later experienced a relapse (median 56.6 U/ml, range 9.5-310.7) compared to patients who did not relapse (median 32.0 U/ml, range 7.4-106.0). Consequently, patients with a sCD30 level higher than median (39.3 U/ml) had a signifi cantly higher risk to experience relapse than patients with sCD30 levels lower than median (RR 3.3, 95% CI 1.1-4.6; p=0.01). Additionally, we analysed whether sCD30 levels were associated with ANCA status. Plasma levels of sCD30 did not diff er signifi cantly between patients positive for C-ANCA by IIF or PR3-ANCA by ELISA and patients who were ANCA negative at 3, 6, and 12 months aft er diagnosis (Figure 3b ). Patients who were positive for PR3-ANCA at 18 or 24 months had signifi cantly elevated sCD30 plasma levels compared to patients negative for PR3-ANCA (p<0.001; p=0.031) (Figure 3b ). Patients who were positive for PR3-ANCA by ELISA at 18 months, already had signifi cantly higher sCD30 levels at 12 months aft er diagnosis (p = 0.034). At 24 months aft er diagnosis patients positive for C-ANCA (IIF) had signifi cantly higher sCD30 plasma levels compared to C-ANCA negative patients (p=0.025).
Levels of sCD30 during follow-up correlated signifi cantly with sIL-2R and CRP. At diagnosis and relapse sCD30 also correlated signifi cantly with sIL-2R but not with CRP.
IL-10
IL-10 is a Th 2-cytokine with immunosuppressive qualities. We studied IL-10 levels longitudinally, and evaluated to what extent increased levels during follow-up might protect against disease relapse in PR3-ANCA-associated vasculitis.
At diagnosis, patients' IL-10 levels were signifi cantly higher than at 3 and 6 months aft er diagnosis (both p < 0.01). In patients with PR3-ANCA-associated vasculitis IL-10 levels were signifi cantly lower 6 months aft er diagnosis than in healthy controls (p<0.05) ( Figure   2c ). IL-10 levels at relapse were signifi cantly higher than at all time points during followup (p<0.01). Plasma IL-10 levels increased during follow-up; at 24 months aft er diagnosis, when immunosuppressive treatment had been stopped, IL-10 levels were signifi cantly higher than at 3, 6, 12 and 18 months aft er diagnosis (p<0.05) (Figure 2c ).
Patients experiencing a relapse within a period of 60 months of follow-up had signifi cantly lower IL-10 levels at 3 months aft er diagnosis than patients who did not relapse. At 3 months aft er diagnosis IL-10 levels higher than median (61 pg/ml) were associated with a signifi cantly reduced risk to experience relapse compared to IL-10 levels lower than median (RR 0.56, 95% CI 0.31-0.98; p=0.044). Plasma IL-10 levels at all time points during follow-up did not diff er between patients who were either positive or negative for ANCA as determined by ELISA and IIF.
BAFF
Th e polyclonal B cell stimulator BAFF has been associated with autoimmunity. We measured plasma levels of BAFF in PR3-ANCA-associated vasculitis and assessed the relation between BAFF and disease-activity, as well as between BAFF and ANCA levels. Plasma levels of BAFF were signifi cantly higher at all time points in patients than in controls (p<0.001) (Figure 2d ). In patients with ANCA-associated vasculitis BAFF levels tended to be higher at diagnosis than at 12 months aft er diagnosis (p=0.051). BAFF levels were signifi cantly higher at 18 months than at 12 months aft er diagnosis (p=0.030) ( Figure   2d ). BAFF levels of patients with a relapse did not diff er signifi cantly from levels in patients without a relapse. Plasma levels of BAFF did not diff er between patients positive and negative for ANCA, as determined by ELISA or IIF.
DISCUSSION
Several observations suggest T cell involvement in ANCA-associated vasculitis. Activated
T cells are present in lesions and T cell help is necessary to produce high affi nity ANCA.
Additionally, elevated plasma levels of the T cell activation markers sIL-2R and sCD30 have been reported in ANCA-associated vasculitis, and levels correlated with disease activity [6, 8, 9] . Both sIL-2R and sCD30 plasma levels diff ered between limited and generalized disease, as well as between active and inactive disease [6, 8, 9] . Also in this study, sIL-2R-and sCD30 levels at diagnosis correlated with disease activity. Plasma levels of sIL-2R and sCD30 were higher at diagnosis than during follow-up. Although immunosuppressive therapy thus resulted in a decrease, plasma levels remained elevated as compared to healthy controls. Both sIL-2R and sCD30 levels subsequently increased while tapering and eventually stopping immunosuppressive treatment, refl ecting increased T cell activity in patients in remission that is not completely suppressed or abrogated by treatment. Th ese fi ndings are in line with the observation that increased percentages of activated T cells are present in patients with sIL-2R, sCD30, IL-10, BAFF in PR3-AAV | 61 AAV in remission [10] . Levels of sIL-2R and sCD30, but not of the B cell activator BAFF, were associated with positive ANCA serology during follow-up. At 18 and at 24 months aft er diagnosis, both patients positive for C-ANCA (IIF) and PR3-ANCA (ELISA) had higher levels of sIL-2R and sCD30 than ANCA negative patients. Th erefore, ANCA-positivity seems part of a broader, possibly T cell driven, immune-activation present in patients with AAV.
Obviously, clinical interpretation of levels of immune markers can be complicated by intercurrent infections. Additionally, our study is limited by its retrospective nature.
Nevertheless, the association of T cell activation with the PR3-ANCA autoantibody response suggests an initiating role for T cell activation in PR3-ANCA-associated vasculitis.
However, levels of sIL-2R and sCD30 did not diff er between patients with PR3-ANCAassociated vasculitis who experienced a relapse and those who did not relapse during followup. In contrast, Schmitt et al found that patients with WG who relapsed had signifi cantly higher sIL-2R levels before disease exacerbation than patients who did not relapse. [6] As current immunosuppressive regimens are insuffi cient to maintain long lasting remission in a major part of patients with PR3-ANCA-associated vasculitis, identifi cation of patients at risk for relapse is important. Our data suggest that the persistent presence of elevated levels of markers for T cell activation, although related with ANCA status, does not identify patients at risk for relapse.
In contrast to sIL-2R and sCD30, IL-10 is a cytokine with immunosuppressive and antiinfl ammatory properties. Regulatory T cell subsets among other cells produce IL-10 [19] .
Additionally, IL-10 is associated with type 2 T helper cells (Th 2) and can promote polyclonal hypergammaglobulinemia [20] . In Systemic Lupus Erythematosus (SLE), IL-10 levels refl ect disease activity [21] . We found that IL-10 levels in patients with ANCA-associated vasculitis were elevated at diagnosis and subsequently decreased. At 6 months aft er diagnosis IL-10 levels were signifi cantly lower as compared to healthy controls. Additionally, low levels of IL-10 3 months aft er diagnosis were associated with increased relapse rate during 60 months of follow-up. Recently, Ohlsson et al reported on the same association between low IL-10 levels in patients with AAV 3-months prior to relapse [11] . In addition, both in WG and MPA, a shift towards the homozygous AA genotype has been found in the IL-10 (-1082) polymorphism [22] . In vitro this genotype correlates with low IL-10 secretion by ConAstimulated peripheral blood mononuclear cells of healthy individuals [23] . Th ese data and our clinical fi ndings suggest that low plasma levels of IL-10 infl uence disease development and exacerbation.
Whereas T cells are operative in production of ANCA, other factors, e.g. BAFF, may be involved as well. BAFF is a member of the tumor necrosis factor (TNF) ligand superfamily and is expressed by monocytes, macrophages, dendritic cells, and, possibly, activated T cells [24] [25] [26] . Since BAFF stimulates all B cells and thereby promotes their survival [27] , it is thought to contribute to autoimmunity by stimulating autoreactive B cells. In patients with SLE, Rheumatoid Arthritis (RA) and Sjögren syndrome, elevated serum levels of BAFF have been found. Levels correlated with serum IgG levels and anti-double standed DNA antibody titers among SLE patients and with rheumatoid factor (RF) titers among seropositive RA patients [12, 28] . Moreover, in Sjögren syndrome, levels of BAFF correlated with both anti-SSA and anti-SSB antibodies and RF. Recently, two groups reported, on elevated levels of BAFF in Wegener's Granulomatosis [29, 30] . We found that levels of BAFF were elevated in patients with PR3-ANCA-associated vasculitis as compared to healthy controls. However, BAFF levels did not correlate with ANCA titers, and ANCA positive patients did not have higher BAFF levels than ANCA negative patients. Also in previous studies, no correlation was found in patients with WG between B cell activation and serum levels of ANCA, RF, IgM and IgG, the latter being markers of polyclonal B cell activation [10] . Th e data, therefore, suggest that elevated BAFF levels are rather a result of a stimulated immune-system than a factor related to the PR3-ANCA response or to disease activity.
In summary, in PR3-ANCA-associated vasculitis, markers of T cell activation are increased at diagnosis and correlate with disease activity. Although immunosuppressive therapy results in a decrease, T cell activity does not normalize. Upon tapering and stopping immunosuppression levels of T cell activation markers rise again, refl ecting increased T cell activity. Th is increased T cell activity is associated with ANCA positivity, and should be viewed as a result of a T cell driven immune-response which could be at the basis of this disease.
